Lixte Biotechnology closes $1.5M registered direct offering of common stock and pre-funded warrants

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Closed registered direct offering of 974,026 shares (or pre-funded warrants) at $1.54 per share for gross proceeds of ~$1.5M.
Offering comprised 210,675 common shares and pre-funded warrants for 763,351 shares; closed July 8, 2025.
Net proceeds to be used for general corporate purposes and working capital.
Spartan Capital Securities acted as exclusive placement agent; TroyGould PC provided legal counsel.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.